A detailed history of American Portfolios Advisors transactions in Myriad Genetics Inc stock. As of the latest transaction made, American Portfolios Advisors holds 67 shares of MYGN stock, worth $920. This represents 0.0% of its overall portfolio holdings.

Number of Shares
67
Holding current value
$920
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$18.21 - $27.88 $1,220 - $1,867
67 New
67 $1.28 Million
Q1 2020

Mar 24, 2023

BUY
$9.78 - $29.53 $567 - $1,712
58 Added 86.57%
125 $1.79 Million
Q4 2019

Mar 24, 2023

BUY
$20.93 - $35.1 $1,213 - $2,035
58 Added 86.57%
125 $3.4 Million
Q2 2019

Mar 24, 2023

BUY
$22.67 - $35.0 $1,314 - $2,030
58 Added 86.57%
125 $3.47 Million
Q3 2018

Mar 24, 2023

BUY
$37.57 - $50.34 $2,179 - $2,919
58 Added 86.57%
125 $5.75 Million
Q1 2018

Mar 24, 2023

BUY
$28.83 - $41.01 $1,672 - $2,378
58 Added 86.57%
125 $3.69 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.11B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.